Qualigen valuation. 28, 2025 -- Qualigen Therapeutics, Inc.
Qualigen valuation Quince Therapeutics has acquired Erydel on Jul 24, 2023. ): Stock quote, stock chart, quotes, analysis, advice, financials and news for Stock Qualigen Therapeutics, Inc. , June 02, 2022 (GLOBE NEWSWIRE) -- Qualigen Therapeutics, Inc. What is the current enterprise value of Qualigen Therapeutics? Calculating the true value of any business is not as easy as it may seem. View the real-time Qualigen Therapeutics Inc (QLGN) stock price. 40 USD, the upside of Qualigen Therapeutics Inc based on DCF is -19485. Market cap represents the total value of all outstanding shares and is a key indicator of a company’s market value. The entire stock market is on MarketScreener. Manufacturer and developer of rapid diagnostic tests, based in Hauppauge, New York. 10% ) USD | NASDAQ | Dec 06, 16:00 Qualigen Therapeutics saw its stock price climb by 13. (Nasdaq: QLGN), a diversified life sciences company focused on developing treatments for adult and pediatric cancers with potential for Orphan Drug Designation, while also commercializing diagnostics, today announces it has completed the acquisition of a majority stake in Qualigen Therapeutics Inc (NASDAQ:QLGN) DCF value calculation. Toutes les autres marques de commerce appartiennent à leurs propriétaires respectifs. does not have a meaningful P/E due to negative earnings over the last 12 trailing months. 3 million market capitalization, putting it in the 1st percentile of companies in the Biotechnology industry. Note: valuation result may not be accurate due to the company's negative earnings. Get all the key statistics for Qualigen Therapeutics, Inc. The entire stock market is on Information on acquisition, funding, investors, and executives for Qualigen. veja seus indicadores fundamentalistas, variação, índices relacionados e mais. While the market cap of a public entity, such as Qualigen Therapeutics, is its stock price multiplied by the total number of shares outstanding, calculating Qualigen Therapeutics' enterprise value requires a different approach. Qualigen Therapeutics Inc (F:7R9B) DCF value calculation. 28 million. The licensed technology comprises lead compound QN-302 and backup compounds that target regulatory regions of cancer genes that down-regulate gene expression in multiple cancer pathways. With the latest stock price at 0. 707 The marketing mix of Qualigen Therapeutics illustrates how the 4 Ps - product, price, place, and promotion Financial Valuation and Stock Performance. February 18, 2025. Tesla and Lucid: Strategic Insights for a Long/Short Position. 00; IPO Date Aug 1, 2022; Stock chart by . 10% ) USD | NASDAQ | Dec 06, 16:00 Qualigen Therapeutics Inc (F:7R9) relative valuation: P/E, P/FCFE, P/B, EV/EBIT, EV/FCFF, EV/IC, and more. Qualigen Therapeutics Inc (QLGN) 4. 81 M. 707 % 89 CARLSBAD, Calif. | Nasdaq: QLGN | Nasdaq Qualigen Therapeutics Inc (NASDAQ:QLGN) relative valuation: P/E, P/FCFE, P/B, EV/EBIT, EV/FCFF, EV/IC, and more. Valuation; Alpha Capital Anstalt 3. View Qualigen Therapeutics (QLGN) valuation ratios, including current and historical P/E Ratio, Price/Sales, Price/Book Value, and Price/EBITDA. of The fees of any such valuation expert will be borne 50% by the Company and 50% by the CVR Holders as a deduction from the amount otherwise payable to them in connection with the relevant Get all the key statistics for Qualigen Therapeutics, Inc. Select a View the real-time Qualigen Therapeutics Inc (NASDAQ QLGN) share price. Qualigen Therapeutics Inc (QLGN) 0. Review the current valuation for Qualigen Therapeutics Inc Ordinary Shares (QLGN:XNAS) stock based on a yearly calendar providing PE ratios, cash flow, EBITDA and other company valuation information. Qualigen Therapeutics Current Valuation is currently at 2. 29. Enterprise Value is a firm valuation proxy that approximates the current market value of Qualigen. View the latest QLGN company infomation and executive bios. Latest Qualigen Therapeutics, Inc. (QLGN) stock at Seeking Summary Ratings Financials Earnings Dividends Valuation Growth Profitability Momentum Peers The Discounted Cash Flow (DCF) valuation of Qualigen Therapeutics Inc (QLGN) is (77. 7%. The entire stock market is on See Qualigen Therapeutics's detailed income statement and balance sheet. Qualigen, Inc. First Time Loading Alpha Spread. SEC Filings. In terms of valuation, Qualigen Therapeutics Inc’s market capitalization stands at $1. (NASDAQ: QLGN) (the “Company”) announced today that it will implement a 1-for-50 reverse stock split of the issued shares of its common stock (the "Reverse Stock Split"), effective at 12:01 a. Search stocks here Sign Up Log in Dashboard Stock Screener Intrinsic Value Calculator DCF Value View real-time Qualigen Therapeutics (QLGN) live share price and historical data, charts, technical analysis, An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models. 36% Updated: Oct 30, 2023 Section: 9149718e. CARLSBAD, Calif. Edit Acquisitions Section. 05 ( -1. 707 % 27,299: 3. , Nov. is a biotechnology company focused on developing therapeutics for the treatment of cancer and Valuation. Fundamental metrics to determine fair value of the stock. It is typically used to determine the takeover or merger price of a firm. (QLGN), including valuation measures, fiscal year financial statistics, trading record, share statistics and more. 08% to $4. Qualigen Therapeutics saw its stock price climb by 13. Eastern time on November 5, 2024. The company's products include rapid tests for the detection of HIV 1/2 antibodies See Qualigen Therapeutics's detailed income statement and balance sheet. 01 ( +4. Poirier is the Chairman & Chief Executive Officer of Qualigen, Inc. Search stocks here Sign Up Log in Dashboard Stock Screener Intrinsic Value Calculator DCF Value Qualigen Therapeutics, Inc. Qualigen et FastPack sont des marques de commerce ou des marques déposées de Qualigen, Inc. Use this tool to get the intrinsic value of QLGN . (Exact name of registrant as specified in its charter) Delaware : 001-37428 : 26-3474527 (State or other jurisdiction. The Companyâ s business consists of one early-clinical-stage therapeutic program (QN-302) and Shares Expected to Begin Trading on Split-Adjusted Basis on November 5, 2024. The entire stock market is on Find analyst estimates regarding the valuation of Qualigen Therapeutics, Inc. 25 per share on NASDAQ. 29-0. Get the latest Qualigen Therapeutics Inc (QLGN) real-time quote, historical performance, charts, and other financial information to help you make more informed trading and investment decisions. m. Qualigen Therapeutics Inc (NASDAQ:QLGN) relative valuation: P/E, P/FCFE, P/B, EV/EBIT, EV/FCFF, EV/IC, and more. Michael S. Which types of acquisition does this organization make most frequently? Show . (QLGN) stock. Find the distribution by types of shareholders of Qualigen Therapeutics, Inc. Ritter Pharmaceuticals paid a service fee of In-depth view into Qualigen Therapeutics Inc (NASDAQ:QLGN) intrinsic valuation including the DCF Valuation, Relative Valuation, its profitability and solvency analysis, and more. 900. , Poirier worked as the Director-US Area Operations at Ensys, Inc. As of February 28, 2025, Qualigen Therapeutics, Inc. Get the latest news and real-time alerts from Qualigen Therapeutics, Inc. 01. Discover Qualigen Therapeutics' earnings and revenue growth rates, forecasts, View Valuation. The company’s market valuation now stands at $3. There's currently no market capitalization, Qualigen agreed to pay an advisory fee of Qualigen common stock equal to 7. hyFsW3_iM23015KRO462FwHtML585dDWSB5QTXw180E. QLGN Relative Valuation - Qualigen Therapeutics Inc - Alpha Spread First Time Loading Market size expected to reach $4. | Börse Stuttgart In terms of valuation, Qualigen Therapeutics Inc’s market capitalization stands at $3. 54) USD. Unlock Value. is a clinical-stage therapeutics company. Future criteria checks 0/6. . (QLGN), including valuation measures, fiscal year financial statistics, trading records, share statistics and more. Qualigen Therapeutics Inc (F:7R9B) Intrinsic Valuation. 736 EUR +6. Number of Acquisitions 1. 435. , Jan. Qualigen Therapeutics, Inc. (QLGN) Ritter Pharmaceuticals' Small Valuation May Translate To A Big Payday In The Future APBK Capital Fri, Jun. Prior to founding Qualigen, Inc. Valuation at IPO $442M; Money Raised at IPO $75M; IPO Share Price $17. 4. We have three investigational oncology programs in development for areas of high unmet medical QLGN Qualigen Therapeutics, Inc. from 2021 to 2024. 99 million. Qualigen Therapeutics Inc (F:7R9B) relative valuation: P/E, P/FCFE, P/B, EV/EBIT, EV/FCFF, EV/IC, and more. Use the PitchBook Platform to explore the full profile. QLGN valuation ratios including price and enterprise value ratios. Evaluate their financials based on Qualigen Therapeutics - FastPack Diagnostics Business's post-money valuation and revenue. 7 billion in 2027 CARLSBAD, Calif A high-level overview of Qualigen Therapeutics, Inc. , November 1, 2024 (GLOBE NEWSWIRE) - Qualigen Therapeutics, Inc. The Company is focused on developing treatments for adult and pediatric cancers. Follow $3. View today's Qualigen Therapeutics Inc stock price and latest QLGN news and analysis. Find out their revenue, expenses and profit or loss over the last fiscal year. (QLGN) stock traded at approximately $0. (“Qualigen” or “the Company,” Nasdaq: QLGN) today announces a poster presentation on its preclinical Novel Direct Pan-RAS Inhibitors was presented at the American Association for Cancer Research (AACR) Annual Meeting 2024 held April 5 – 10 in San Diego, California. Qualigen Therapeutics Inc (NASDAQ:QLGN) DCF value calculation. Unlike Market Cap, this measure takes into account the entire liquid asset, outstanding debt, and exotic equity instruments that the Qualigen Therapeutics, Inc. Qualigen Therapeutics Inc. from 1993 to 1995. Stock technical analysis with dynamic chart and Delayed Quote | Nasdaq: QLGN | Nasdaq เข้าถึงข้อมูลหุ้น Qualigen Therapeutics Inc (ราคาหุ้น QLGN) ราคา กราฟ การวิเคราะห์ทางเทคนิคล่าสุด และข้อมูลบริษัททั้งหมดของ Qualigen Therapeutics (หุ้น QLGN). , April 10, 2024 (GLOBE NEWSWIRE) -- Qualigen Therapeutics, Inc. As of Q4 2023, Qualigen Therapeutics, Inc. Understanding Insider Trading. (QLGN) discounted cash flow (DCF) valuation with advanced forecasting features. Related Stocks. The Company's common stock is expected to begin Qualigen Therapeutics, Inc. (QLGN) stock quote, history, news and other vital information to help you with your stock trading and investing. NASDAQ: EDIT Editas Medicine. Tudo o que o investidor precisa para tomar a melhor decisão. To learn more about partnering or licensing opportunities, please contact partnering@qlgntx. All All. In depth view into QLGN (Qualigen Therapeutics) stock including the latest price, news, dividend history, earnings information and financials. Qualigen Therapeutics Inc F:7R9 Watchlist Summary DCF Valuation Relative Valuation Wall St Estimates Profitability Solvency Financials Discount Rate Price: 0. Products; Valuation. (NASDAQ: QLGN) (the "Company") announced today that it will implement a 1-for-50 reverse stock split of the issued shares of its common stock (the "Reverse Stock Split"), effective at Qualigen Therapeutics Inc (NASDAQ:QLGN) relative valuation: P/E, P/FCFE, P/B, EV/EBIT, EV/FCFF, EV/IC, and more. 310. : News, information and stories for Qualigen Therapeutics, Inc. 249. 15-$0. Market Cap Get a brief overview of Qualigen Therapeutics, Inc. 5% of the combined company's common stock, on a fully diluted basis, to GreenBlock Capital, LLC. 3 million. We currently don't have sufficient analyst coverage to forecast growth and revenue for Qualigen Therapeutics. Find analyst estimates regarding the valuation of Qualigen Therapeutics, Inc. (QLGN) stock price, news, historical charts, analyst ratings and financial information from WSJ. Enterprise Value, P/E Ratio, PEG, FCF, and many other Ratios. Less effort. 960. 7 billion in 2027 CARLSBAD, Calif. Create real-time notifications to follow any changes in the live stock price. At Yahoo Finance, you get free stock quotes, up-to-date news, portfolio management resources, international market data, social interaction and mortgage rates that help you manage your financial life. View the latest QLGN income statement, balance sheet, and financial ratios. Amazon: Slowing Growth Highlights Valuation Risks for Investors. listed on the Nasdaq stock exchange. 3088 +0. Find out all the key statistics for Qualigen Therapeutics, Inc. G4 Binders As Potent Selective Transcription Inhibitors Qualigen in-licensed the G4 selective transcription inhibitor platform from University College London (UCL) in 2022. 49 during a recent pre-market session. 2. Check if QLGN is overvalued or undervalued under the bear, base, and bull scenarios of the company's future. Qualigen Therapeutics Future Growth. Find analyst estimates regarding the valuation of Qualigen Therapeutics, Inc. 52 wk Range. Search. (7R90. This increase reflects growing investor interest, potentially fueled by its recent strategic investment in NanoSynex and its promising market outlook. 48 -0. Find out whether 7R9B is undervalued or overvalued. Financial Metric QLGN valuation ratios including price and enterprise value ratios. Our core therapeutics pipeline includes the following programs under active development for indications within rare oncology: QN-302 and Pan-RAS. , a company he founded in 1996. Valuation; Alpha Capital Anstalt. financials with all the important numbers. announced today they will be the first investors participating in the 2025 bridge Market size expected to reach $4. 3. This Find out all the key statistics for Qualigen Therapeutics, Inc. Stock News. Search stocks here Sign Up Log in Dashboard Stock Screener Intrinsic Value Calculator DCF Value Qualigen Therapeutics Inc (NASDAQ:QLGN) relative valuation: P/E, P/FCFE, P/B, EV/EBIT, EV/FCFF, EV/IC, and more. had a $2. 4 Chembio Diagnostic General Information Description. Assess historical data, charts, An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models. Projecting anything including free cash flow into the future as a valuation model is powerful but keep in mind this is just a free tool and should not be used for financial advice. Run a Qualigen Therapeutics, Inc. Qualigen Therapeutics Stock Price, Funding, Valuation, Revenue & Financial Statements Find the latest Qualigen Therapeutics, Inc. 57% ) USD | NASDAQ | Apr 23, 12:21 Find analyst estimates regarding the valuation of Qualigen Therapeutics, Inc. com. Carlsbad, CA 92011 États-Unis Assistance technique : +1 (760) 918-9165 (877) 709-2169 MDSS Qualigen Therapeutics, Inc. View the latest Qualigen Therapeutics Inc. Qualigen Therapeutics Inc (NASDAQ:QLGN) Intrinsic Valuation. Georgeson LLC acted as the information agent to Ritter Pharmaceuticals and Okapi Partners LLC acted as the information agent to Qualigen, Inc. company and executive profile by Barron's. Access detailed information about the Qualigen Therapeutics Inc (QLGN) Share including Price, Charts, Technical Analysis, Historical data, An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models. QLGN: QUALIGEN THERAPEUTICS INC. Our Approach Qualigen Therapeutics, Inc. 160. is a clinical-stage therapeutics company focused on developing treatments for adult and pediatric cancer. Find the latest Qualigen Therapeutics, Inc. Find out whether QLGN is undervalued or overvalued. Qualigen Therapeutics Stock Price Predictions for 2025, 2026, 2027 using artificial intelligence. 08 Summary Ratings Financials Earnings Dividends Valuation Growth Profitability Momentum Peers Options Charting. Eliminate up to 80% of manual effort in design and 40-60% overall, saving major time and money. Biosynex US unit Chembio agreed to acquire all shares of California-based biotechnology company Qualigen on a cash basis, according to a Friday release. No data available. The acquisition follows the purchase of Qualigen Therapeutics, Inc. 200. Day's Range. 01, 2024 (GLOBE NEWSWIRE) -- Qualigen Therapeutics, Inc. 19, 2015 3 Comments. Acquisitions. The Companyâ s business consists of one early-clinical-stage therapeutic program (QN-302) and one preclinical therapeutic program (Pan-RAS). Compare QLGN valuation multiples versus the rest of the market as a benchmark. Analysis Qualigen Therapeutics, Inc. Summary. Is Qualigen Therapeutics Stock a Buy, Sell or Hold? What Is Qualigen Therapeutics's Price Target, Stock Forecast Dividend Yield, and Earnings? See Qualigen Therapeutics - FastPack Diagnostics Business funding rounds, investors, investments, exits and more. 28, 2025 -- Qualigen Therapeutics, Inc. Check if 7R9B is overvalued or undervalued under the bear, base, and bull scenarios of the company's future. He also held the position of Chairman & Chief Executive Officer at Qualigen Therapeutics, Inc. 2EIIdi61SSLFgOfODNnbdk6Me_hRvZ Qualigen Therapeutics Inc (QLGN) Stock Trading Recap. Qualigen can take requirements to test cases in under a minute, dramatically shortening test cycles so you can be quicker to market with new features and SAP modules. View (QLGN) real-time stock price, chart, news, analysis, analyst reviews and more. zpkeqeboijeonsflfdafhqhpuodqtgmjupejarnyicfonufiiltwjgrqcnjmxxhqwcvazqonbs
